Company Profile - Biotech
Zag Bio
Zag Bio
zags at autoimmunity.
A Cambridge startup aiming drugs at the thymus - the one organ that teaches the immune system who belongs.
A Cambridge startup aiming drugs at the thymus - the one organ that teaches the immune system who belongs.
Walk into Zag Bio today and you will find a small team in Cambridge fixated on an organ most adults have written off. The thymus shrinks as you age. Textbooks treat it as a childhood relic. Zag Bio treats it as the control room. In October 2025 the company stepped out of stealth with $80 million and a single, stubborn idea: if autoimmune disease is the immune system attacking the body, the fix is not to mute the immune system - it is to re-educate it where the education happens.
That is the whole company in one sentence. Everything else - the antibodies, the pipeline, the investor roster that reads like a pharma conference badge wall - hangs off that one bet.
The thymus has been inaccessible to drugs of all types.
- Jason F. Cole, J.D., Chief Executive OfficerIt is an unfashionable place to plant a flag, which is precisely the point. Plenty of biotechs promise to "modulate the immune system." Very few pick the one address in the body where tolerance is actually written into developing cells, and then build a delivery truck to get there.
Here is the uncomfortable part of being human: your immune system is trained, not born knowing things. T cells pass through the thymus, where they learn the difference between you and a threat. Most that fail the test are removed. The ones that pass go out to patrol. The system is elegant right up until a cell that should have flunked slips through and decides your pancreas is the enemy. That is Type 1 diabetes. That is a long list of other diseases too.
The standard answer for decades has been blunt: turn the immune system down. It works, sort of, and it costs you - infections, side effects, a body left less able to defend itself. You are trading one problem for a quieter one.
The thymus is the only location where self-antigens are presented to induce T cell central tolerance.
- Zag Bio, on why it picked the hardest targetZag Bio's read on the situation is almost annoyingly logical. If the immune system attacks the body because it was never properly taught not to, then suppression is treating the symptom. The lesson was missed in the thymus. So go back to the classroom. The trouble, of course, is that nobody had figured out how to get a drug to show up for class.
Zag Bio was founded and incubated inside Polaris Partners, then assembled around people who had spent careers in the parts of biology most teams avoid. The co-founders bring thymus biology, autoimmune drug development, and a willingness to be early.
Entrepreneur Partner at Polaris Partners; serial company-builder who incubated Zag Bio.
Professor of Immunobiology at Harvard Medical School; long-running authority on immune tolerance.
Leads the science behind the bifunctional-antibody platform.
Biotech executive with deep autoimmune-disease drug-development experience.
To run it, the board recruited Jason F. Cole, J.D. as CEO - formerly chief executive of SalioGen Therapeutics and chief strategy and financial officer at bluebird bio. The bet they all signed up for is uncomfortable on purpose: spend years and tens of millions making the thymus druggable, on the theory that doing the hard thing once is better than suppressing immune systems forever.
Taking a new direction to treat autoimmunity.
- The company tagline, and a fair summary of the wagerThe platform is a class of engineered bifunctional antibodies. One end carries a self-antigen - say, a piece of a pancreatic beta cell. The other end knows how to find the specialized antigen-presenting cells inside the thymus. Put them together and you have a courier that hand-delivers the body's own ID badge to the exact place where developing T cells learn whose side to be on.
Two things then happen in the classroom. The thymus expands antigen-specific regulatory T cells - the peacekeepers - while depleting the self-reactive effector cells that would have caused trouble. Mature, well-trained Tregs leave the thymus and travel to the tissue under attack. Tolerance, restored at the source, then enforced in the field.
Not immunosuppression. Re-education - with the curriculum delivered to the one room that grants the degree.
- How the platform differs from the standard playbookThe lead program is ZAG-101, aimed at Type 1 diabetes. It delivers beta-cell antigens to the thymus as a tolerogenic therapy meant to prevent or delay the disease before it does its damage. The company has been running IND-enabling studies with a goal of entering the clinic around late 2026. Behind it sits a discovery pipeline pointed at other antigen-specific autoimmune diseases - because once you own the delivery truck, you can change the cargo.
Early-stage biotech is mostly conviction, so the honest proof here is who showed up to write checks. The Series A was co-led by Polaris Partners and the JDRF T1D Fund - the second of which only backs work that could change Type 1 diabetes. Then the part that makes people look twice: AbbVie Ventures, Sanofi Ventures, and Regeneron Ventures all participated in the same $80 million round.
Those three are competitors. Getting them into one cap table is less a celebrity endorsement and more three independent due-diligence teams arriving at the same verdict. Rounding out the syndicate: Mission BioCapital, Lightspeed Venture Partners, KdT Ventures, Boxer Capital, and Pear VC.
Three rival pharmas, two venture funds, and one organ nobody else wanted. The syndicate is the headline.
- On the $80M Series A, October 2025The stated mission is to develop more precise, potent, and impactful medicines for immune-mediated diseases - by targeting the thymus and restoring central immune tolerance rather than broadly suppressing the immune system. Read plainly: stop treating the whole body to fix a local argument.
If it works for Type 1 diabetes, the logic does not stop there. The same delivery approach could carry different antigens for different antigen-specific autoimmune diseases. That is the quiet ambition under the modest team size - not one drug, but a way of making many.
Most autoimmune drugs turn the immune system down. Zag Bio is trying to turn it smart.
- The difference the company is betting its years onReturn to that 26-person team and the organ everyone else forgot. Nothing about the science is guaranteed - ZAG-101 still has to clear IND-enabling studies, still has to enter the clinic, still has to work in people. Biology has humbled smarter plans. The honest status is "promising and unproven," and Zag Bio would tell you the same.
But the reframe is already doing work. For decades the thymus was a footnote and autoimmunity was a problem you suppressed. Zag Bio is treating the footnote as the headline and suppression as a placeholder we have tolerated too long. If they are right, a child at risk of Type 1 diabetes might one day get a therapy that teaches their body to stand down - before the damage, not after.
The relic, it turns out, was the control room the whole time. Zag Bio just decided to knock.
Video interviews and a product demo were not publicly available at the time of writing - check the company's LinkedIn and website for the latest. Figures and dates reflect public sources as of the company's October 2025 launch and may have advanced since.